英国葛兰素史克GSK GlaxoSmithKline 葛兰素史克中国    葛兰素史克全球    
葛兰素史克公司，由葛兰素威康（Glaxo Wellcome）和史克必成（SmithKline Beecham）强强联合,于2000年12月成立。  
作为世界领先的制药业巨擘，葛兰素史克公司秉承以研究开发为基础的一贯理念，凭藉公司本身的技术潜力和资源优势，在当今瞬息万变的医疗保健领域保持强劲的增长势头。葛兰素史克公司的历史可追溯至18世纪，经历两个多世纪的不断创新和数次合并，葛兰素威康和史克必成于2000年12月强强联合，在医药领域确立了世界级的领先地位。
      葛兰素史克公司总部设在英国，以美国为业务营运中心，在全球药品市场中约占近7%的份额。公司在全球拥有10万余名既掌握专业技能又有奉献精神的出色员工，在世界37个国家拥有82个生产基地，年产药品40亿盒，产品遍及全球市场。2006年，葛兰素史克全球销售总额达232亿英镑，按恒定汇率同比增长9%。

葛兰素史克公司的药品主要用于六大领域――抗哮喘、抗病毒、抗感染、精神卫生、糖尿病和消化系统，癌症药物的研发也正迅猛发展。葛兰素史克的疫苗产品居世界领先地位，全球25%的疫苗是由葛兰素史克提供的。此外，在消费保健品领域，葛兰素史克亦居世界前列，主要产品包括非处方药、口腔护理产品、戒烟产品和营养保健饮料。
葛兰素史克中国
葛兰素史克公司在中国的历史最早可追溯至20世纪初叶。自20世纪80年代以来，在中国政府改革开放政策的感召下，公司在中国积极投资，将最先进的制药技术、最优质的产品、最新型的商业模式、最现代化的管理理念和市场营销技巧引入了中国。

葛兰素威康和史克必成公司于2000年12月完成全球性合并，2002年，葛兰素史克(中国)投资有限公司全面完成业务整合并正式宣布成立，成为中国目前规模最大的跨国制药企业之一。公司业务由处方药、非处方药、疫苗和消费保健品4大部分组成，投资公司和地区总部位于北京，主要业务中心分设在上海、天津和香港。

葛兰素史克是最早在中国成功兴建合资企业的外国制药公司之一。在进入中国的20多年间，葛兰素史克先后成立了5家公司，目前2家为合资企业，总注册资本超过2.3亿美元。目前公司在全国28个主要城市(包括香港)设立了办事机构，在全国拥有近3000名员工，为中国的医药行业培养了一大批高素质的商业管理人员和技术骨干。

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.

But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.

It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.

As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs. Every hour we spend more than £300,000 (US$562,000) to find new medicines.

We produce medicines that treat six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

GSK worldwide
GlaxoSmithKline (GSK) is a leading, research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.

GSK's history can be traced back to the 18th century. By the end of the 20th century, due to the successful merger of two global pharmaceutical giants, Glaxo Wellcome and SmithKline Beecham, GSK is well positioned to become the indisputable leader of the pharmaceutical industry worldwide.

Headquartered in the UK and with operations based in the US, GSK is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. The company's total sales for 2006 were ￡23.2 billion, up 9% in CER terms. GSK has 82 manufacturing sites in 37 countries that supply products to the global markets. GSK has over 100,000 highly skilled and dedicated employees worldwide.

GSK produces medicines that treat six major disease areas ---- asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer. GSK also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks.

A long and successful heritage in China
GSK's history in China can be traced back to the early 20th century. Since the 1980s, GSK has actively invested in China by contributing state-of-the-art pharmaceutical technologies, innovative products, new business models, modern management concepts and sales and marketing skills. 

Since the completion of the global merger between Glaxo Wellcome and SmithKline Beecham in December 2000, GSK has maintained a leading position within the pharmaceutical community. In 2002, GlaxoSmithKline (China) Investment Co. Ltd. was officially established and became one of the largest multinational pharmaceutical companies in China.

Among its major business units in China, Prescription Medicines, Vaccines, Over-the-Counter (OTC) Medicines and Consumer Healthcare are headquartered separately in Shanghai, Tianjin and Hong Kong. Beijing is also the base and area centre for the holding company GlaxoSmithKline (China) Investment Co. Ltd.

GSK is one of the first foreign pharmaceutical companies to establish successful joint ventures in China. To date, more than twenty years after its initial investment in China, GSK has established five companies with a total registered capital of US$230 million. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

Currently, GSK China has offices in twenty-eight major cities (including Hong Kong) and five legal entities encompassing four manufacturing facilities, two joint ventures and near 3000 employees nationwide.